Mapp Biopharmaceutical, Inc.
Publicly observedSan Diego, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Diego | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Mapp Biopharmaceutical, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | M9V9QTHR1H28 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant24 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of highly potent human monoclonal for RSV immunoprophylaxis
USD 993,435.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant24 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of highly potent human monoclonal for RSV immunoprophylaxis
USD 993,353.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant9 Jun 2025Publicly observed
NIH SBIR/STTR award: A Novel Cost-Effective Multispecific Therapeutic for Dengue
USD 294,583.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.